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Abstract— Various novel 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins have been synthesized by reaction of 
6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones with Vilsmeier reagent. The similar 2-(N-substituted 
amino) derivatives were prepared by nucleophilic replacement reaction of the 2-methylthio moiety by appropriate 
amines. The 2-oxo derivatives (i.e., 5-deazaflavins) were obtained by acidic hydrolysis of the 2-methylthio 
derivatives. The antitumor activities against CCRF-HSB-2 and KB cells and the antiviral activities against HSV-1 
and HSV-2 have been investigated in vitro, and many compounds showed promising antitumor activities. 
Furthermore, AutoDock molecular docking into PTK has been done for lead optimization of these compounds as 
potential PTK inhibitors. Whereas, the designed 2-deoxo-5-deazaflavins connected with amino acids at the 
2-position exhibited the good binding affinities into PTK with more hydrogen bonds. 
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1. Introduction 
 
Design and synthesis of 5-deazaflavin and flavin analogs as potential cancer chemotherapeutic agents have been 
in progress in our laboratory.1-6 Recently, we have reported the significant potential antitumor activities of 
10-substituted 2-deoxo-2-phenyl-5-deazaflavins and flavin-5-oxides against NCI-H 460, HCT 116, A 431, 
CCRF-HSB-2 and KB cells (Scheme 1).1 5-Amino-5-deazaflavins also revealed antiproliferative activity against 
L1210 and KB cells.7 10-Aryl-5-deazaflavin derivatives were preliminarily reported to act as inhibitors against E3 
activity of HMD2 in tumors that retain wide-type P53.8 Actually, 5-deazaflavins have attracted great interest 
because of their homologues as potential riboflavin antagonists, bio-reductive cofactors for the naturally occurring 
flavins, for example, F420, and potent antitumor agents.9 The role of tyrosine kinase in the control of cellular 
growth and differentiation is central to all organisms and the tyrosine kinase has been found to participate in 
human neoplastic diseases. Tyrosine kinase inhibitors and their potentials in the clinical applications are well 
documented by dramatic examples such as Gleevec, Iressa and Herceptin. Several tyrosine kinase inhibitors are 
undergoing human trials and several are in the pipeline of drug discovery.10 Molecular docking has been a focus 
of attention for many years. Generally speaking, today’s flexible docking programs such as AutoDock are able to 
predict protein-ligand complex structures with reasonable accuracy and speed.11 One of the most reliable, robust 
and popular energy-based docking packages is AutoGrid/AutoDock because it allows a very efficient docking of 
flexible ligands (e.g. substrates, drug candidates, inhibitors, peptides, etc.) onto receptors (e.g. enzymes, 
antibodies, nucleic acids, etc.).12  
 
 
 
Despite the large number of publications on chemistry of 5-deazaflavin and related compounds, the information of 
2-methylthio- and 2-(N-substituted amino)-2-deoxo-5-deazaflavins is none yet. The above circumstances led us to 
seek a convenient synthetic route to the 2-methylthio- and 2-(N-substituted amino)-2-deoxo-5-deazaflavins to 
search their potential antitumor activities. In this study, we describe the facile synthesis of 10-alkyl-2-deoxo-2- 
methylthio-5-deazaflavins as key compounds for antitumor active derivatives. These compounds were used as 
versatile intermediates for synthesis of the various amino coupling derivatives by nucleophilic substitution 
between 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins and suitable primary and secondary alkylamines. 
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Furthermore, they were used in a novel route for the preparation of 5-deazaflavins {pyrimido[4,5-b]quinoline- 
2,4(3H,10H)-diones} in good yields. These compounds were investigated for their in vitro antitumor and antiviral 
activities. In fact, many of the synthesized compounds showed promising antitumor activities against 
CCRF-HSB-2 and KB cells. Also the SAR study was carried out with the aid of molecular modeling using 
AutoDock for the aim to get designed compounds possessing higher binding affinities into c-kit receptor of PTK. 
The correlation between the growth inhibitory activities (IC50, µg/mL) of the synthesized 5-deazaflavins against 
tumor cells and the AutoDock binding free energies was investigated, where a fairly good correlation for some 
compounds was obtained. Also the computationally designed 10-alkyl-2-deoxo-5-deazaflavins connected with 
amino acids at the 2-position exhibited preferential binding affinities into PTK with more hydrogen bonds.  
 
2. Results and discussion 
 
2.1. Chemistry 
 
The requisite 6-chloro-2-methylthiopyrimidin-4(3H)-one was prepared by treatment of 4-amino-6-chloro-2- 
methylthiopyrimidine13 with NaNO2 in glacial acetic acid according to the method of Israel, et al.14  The 
4-amino-6-chloro-2-methylthiopyrimidine was obtained by reaction of thiourea and ethyl cyanoacetate, followed 
by methylation of the produced 4-amino-6-hydroxy-2-mercaptopyrimidine with dimethylsulfate and by 
chlorination with phosphoryl chloride. 6-Chloro-2-methylthiopyrimidin-4(3H)-one was also prepared by 
alternative route from S-methylation of thiobarbituric acid with MeI,15 followed by chlorination with phosphoryl 
chloride,16 and partially basic hydrolysis of the obtained 4,6-dichloro-2-methylthiopyrimidine.17 The key 
intermediate, 6-(N-monoalkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–j), were synthesized by the 
treatment of 6-chloro-2-methylthiopyrimidin-4(3H)-one14,16 with appropriate N-alkylanilines in n-butanol under 
reflux for 12–72 h in 55–83 % yields as shown in Scheme 2. The commercially unavailable N-monomethylated 
anilines were prepared from the suitable aniline derivatives in two steps. Thus, the N-formylation of anilines with 
ethyl formate under reflux for 15 h gave the corresponding N-arylformamides, followed by reduction of the 
N-arylformamides using LiAlH4 in dry THF to afford the corresponding N-monomethylated anilines.18 The 
intended 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2a–j) were prepared by the reaction of 1a–j with 
Vilsmeier reagent (N,N-dimethylformamide–phosphoryl chloride) at 90 °C for 0.5–2 h to afford the products as 
yellow needles in 71–99 % yields. Since the direct cyclization of 6-(N-methylanilino)-4-oxo-2-thioxo-1,2,3,4- 
tetrahydropyrimidines was not successful, the 2-thioxo moiety should be protected by methylation before the 
cyclization with Vilsmeier reagent.  
 
The preparation for such N-substituted amino derivatives by reaction of alkylthio derivatives with appropriate 
primary or secondary amines has long been utilized in heterocyclic chemistry. Many of these reactions require 
rather strenuous conditions and are usually carried out in a stainless steel sealed vessel except when amines of 
high boiling point are used.19 The pyrimidine moieties of 5-deazaflavins to undergo nucleophilic substitution 
reactions on the carbons adjacent to ring nitrogens are well authenticated and readily explicable in view of the π 
electron-deficient nature. Therefore, the various aminations were applied for the replacement of 2-methylthio  
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group by appropriate amines for the purpose of syntheses of 2-amino- and 2-(substituted amino)-10-alkyl-2- 
deoxo-5-deazaflavins  {2-amino- and 2-(substituted amino)-10-alkylpyrimido[4,5-b]quinolin-4(10H)-ones} 
(3a–e, 4a–c, 6, and 7a–q) as shown in Scheme 3. Namely, 10-alkyl-2-deoxo-2-dimethylamino-5-deazaflavins 
(3a–e) were prepared by heating the suitable 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2) with aqueous 
dimethylamine in a stainless steel sealed vessel at 135 °C for 4 h to afford the corresponding products as yellow 
needles in 59–96 % yields. Whereas, the 10-alkyl-2-amino-2-deoxo-5-deazaflavins (4a–c) were prepared by 
fusion of the suitable 2 with ammonium acetate at 160–165 °C for 0.5–3 hours to afford the corresponding 
products as yellow needles in 57–77 % yields. A similar treatment of 2-deoxo-10-methyl-2-methylthio-5- 
deazaflavin (2a) with n-butylammonium acetate (prepared in situ) at 150–165 °C for 1–3 hours resulted in the 
formation of 2-n-butylamino-2-deoxo-10-methyl-5-deazaflavin (6) as a yellow crystalline solid in 91 % yield. 
Moreover, a variety of 2-(substituted amino)-10-alkyl-2-deoxo-5-deazaflavins (7a–q) were prepared by the facile 
method involving reflux of compound 2 with an appropriate morpholine, piperidine, N-methylpiperazine, 
N-methyl-N-ethanolamine, ethanolamine, or n-octylamine in n-butanol for 2–5 h. All products 7a–q were 
obtained as bright yellow needles in quite good yields of 70–99 %. For all the above mentioned reactions which 
involve treatment with different amines, the excess volatile amines were removed by concentration in vacuo. 
Whereas, the amines of high boiling point were removed by leaching from the residue with water or ethanol for 
piperidine, morpholine, N-(2-hydroxyethyl)-N-methylamine, and N-methylpiperazine, and petroleum ether for 
n-octylamine to get the amine-free products. Acidic hydrolysis of some 10-alkyl-2-deoxo-2-methylthio-5- 
deazaflavins (2) in 5N hydrochloric acid by heating under reflux for 1–2 h gave the corresponding 10-alkyl-5-de- 
azaflavins (5a–c) as yellow needles in 78–91% yields as shown in Scheme 3.  
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UV-vis, IR, and NMR spectra and elemental analyses were used for determination and identification of the newly 
assigned structures. The structures of the key intermediates 1a–j were confirmed in particular by the presence of a 
proton resonance at the 5-position as a singlet signal at 4.62–5.08 ppm in 1H NMR spectra. The cyclized 
10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2a–j) showed a characteristic singlet signal due to the C5-proton in 
the lower field at 9.09–9.63 ppm. It is implying that the methine at the 5-position of 2a–j is more 
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electron-deficient than the other methines. Any substituent at the benzene ring led this singlet signal of the 
C5-proton to the slight upfield, except for 2j (2-deoxo-6,9-dimethoxy-10-methyl-2-methylthio-5-deazaflavin), 
which exhibits this signal in more downfield at 9.63 ppm. This can be explained by the possible formation of a 
hydrogen bond between the oxygen atom of 6-OMe moiety and the proton at the 5-position. This suggestion is 
supported by the similar effect between 9-OMe group and the N10-methyl moiety of 2j, that is, the chemical shift 
of methyl group at the 10-position shown in more downfield region at 4.48 ppm in comparison with N10-methyl 
moieties of other derivatives appeared in the range of 4.21–4.35 ppm. This effect was also clearly observed in the 
UV spectrum of 2j, which indicated some hypsochromic shift, compared with other spectra of 2. Considering the 
1H NMR spectra, the 2-deoxo-5-deazflavin derivatives (3–7) are characterized by disappearance of the strong 
characteristic singlet signal of the 2-methylthio group, which were assigned for compounds 2a–j at 2.56–2.63 ppm. 
The 2-(substituted amino) derivatives (3, 4, 6, and 7) and 5-deazaflavins (5) showed a characteristic singlet signal 
of the C5-proton in the lower field at 8.77–9.12 and 8.93–9.0 ppm, respectively. The methine protons (8.77–9.12 
ppm) at 5-position for 3, 4, 6, and 7 showed in upper field than those (9.09–9.63 ppm) of 2a–j, due to the higher 
electron donating properties of the 2-(substituted amine) groups in comparison with that of the 2-methylthio 
group. 
Regarding the 1H NMR of 10-alkyl-2-deoxo-2-dimethylamino-5-deazaflavins (3a–e), it was noticed that the 
N10-methyl derivatives (3a,c–e) exhibited the equivalent N2-dimethyl groups as an equivalent singlet signal of 6H 
integral almost at 3.33 ppm. Whereas, the N10-ethyl derivative (3b) exhibited the nonequivalent N2-dimethyl 
groups as two singlet signals at 3.34 and 3.48 ppm due to the steric hindrance of longer chain of ethyl group at the 
N-10 position.  
 
 
 
Interestingly, the phenomenon of reversible interconversion of two isomers at 27 °C in case of the 2-monoalkyl- 
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amino (secondary amino) derivatives (6 and 7p,q) was observed as tautomerism in 1H NMR spectra. The twin 
overlapped spectra of approximately (1:2 or 2:1) ratio of the 2-monoalkylamino and 2-monoalkylimino tautomers 
in (CD3)2SO were obtained for the two resonance species (tautomers). Especially, such duplicated spectra were 
observed in the range of 4.0–9.0 ppm based on the tautomers of the guanidine adjacent to carbonyl group. At 
higher temperature of 90–100 °C, the coalescence of the duplicated spectrum was observed to produce the single 
spectrum. As indicated in Figure 1 (A) for compound 6, the 1H NMR spectrum at 27 °C exhibited two singlet 
signals of C5-H and N10-Me at 8.81 and 8.87 ppm and at 4.05 and 4.14 ppm, respectively, and other protons at 6, 7, 
8, and 9-positions were also dupulicated. On the other hand, in the case of 100 °C, the singlet signal at 8.80 and 
4.07 ppm, which was attributable to the C5-H and N10-Me, respectively, was appeared as shown Figure 1 (B) and 
the duplicated spectral signals for other protons also coalesced. The 2-n-butylimino tautomer is proposed 
predominantly at higher temperature because it has a heat of formation (PM3-Mozyme) of 36.23 kcal/mol which 
is higher than that of 2-butylamino tautomer (16.95 kcal/mol). This phenomenon is mainly attributed to the 
presence of a secondary amine at the 2-position, whereas it does not take place in case of 2-substiuted primary and 
teriary amines, for example. compounds 4a–c and 7a–o, respectively. 
 
 
 
The structural identity of the prepared compounds was verified by UV-vis absorption spectra. The spectra for 
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10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2a–j) located in shorter wavelength region in comparison with 
those for previously reported 2-deoxo-2-phenyl-5-deazaflavin derivatives,1 which have more conjugated ring 
system. The UV absorption spectra of the 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–j) showed 
one absorption maximum at 239–246 nm together with two absorption shoulders at 259–275 and 287–293 nm. 
Whereas, the tricyclic 5-deazaflavins (2a–j) showed five absorption maxima at 213–231, 259–275, 278–291, 
311–351 and 403–450 nm. The absorption band at 259–275 nm was shown as a maximum absorption peak or a 
shoulder. Compound 2j indicated the characteristic blue shift (hypsochromic shift) in all wavelength regions in 
comparison with those of 2a–i. This may be attributed to the hydrogen bond formation between the oxygen atom 
of 6-OMe moiety and C5-proton of 2j. This hinders the delocalization of the lone pair on oxygen of 6-OMe to the 
ring system by the hydrogen bond. The UV spectra of 2-(substituted amino)-10-alkyl-2-deoxo-5-deazaflavins (3, 
4, 6, and 7) showed five absorption maxima at 220–225, 268–288, 318–326, 407–428 and 424–454 nm, together 
with an absorption shoulder at 383–404 nm, except for compound 7n. All 5-deazaflavin analogs (2–7) showed 
yellow color owing to the presence of absorption maximum at 400–440 nm in the longest wavelength. Generally, 
the UV spectra of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2) exhibited longer wavelength than those of 
2-(substituted amino)-10-alkyl-2-deoxo-5-deazaflavins and 5-deazaflavins (3–7) as represented in Figure 2 for 
compounds 1a, 2a, 5a, and 7a. This is attributed to the S-atom which causes a generally red shift (bathochromic 
shift) in the spectrum due to its easier polarizability,20 Thus, the spectum of 
2-deoxo-10-methyl-2-methylthio-5-deazaflavin (2a) exhibited the bathochromic shift of ca. 20 nm longer 
wavelength than that of 5-deazflavin (5a) in all UV and visible regions.  
 
2.2. In vitro antitumor activities of 5-deazaflavins and their 2-(N-substituted amino) derivatives against human 
tumor cell lines 
 
The compounds (2–5 and 7) synthesized in this study were tested in vitro for their growth inhibitory activities 
against two human cultured tumor cell lines, that is., human T-cell acute lymphoblastoid leukemia cell line 
(CCRF-HSB-2) and human oral epidermoid carcinoma cell line (KB). The antitumor agent, cytosine arabinoside 
(Ara-C), was used as positive control. 
As can be seen in Table 1, although all compounds of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2) and 
10-alkyl-2-deoxo-2-dimethylamino-5-deazaflavins (3) were inferior antitumor activities compared to Ara-C, they 
have been found to show significant antitumor activities against CCRF-HSB-2 cell line. Among them, the 
compounds 2a,h, 3b and 4b indicated better activities of less than 2.0 µg/mL (IC50). Against KB cell line they 
exhibited good growth inhibitory activities of about one-tenth antitumor potency of Ara-C (IC50: 0.23 µg/mL), that 
is, the IC50 of compounds 2a,h, 3b, and 4b were 1.97, 1.73, 3.96 and 1.00 µg/mL, respectively. The 
2-deoxo-5-deazaflavins may reveal fairly good and less toxic antitumor activities in comparison with Ara-C. 
Moreover, compounds 2b,f,i,j, 6, and 7h,l,n exhibited reasonable potential growth inhibitory activities of ca. 
5.0–7.0 µg/mL (IC50) against CCRF-HSB-2 cell line. Also compounds 2b,f, 6 and 7q exhibited prospective growth 
inhibitory activities of ca. 5.0–8.0 µg/mL (IC50) against KB cell line.  
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On the other hand, the anti-herpes simplex virus activities of these flavin analogs were investigated in vitro against 
HSV-1 and HSV-2 according to the known procedure,21, 22 using acyclovir as a positive control. The potency of 
aniviral activity of each compound is expressed as a minimum inhibitory concentration required to reduce virus 
plaque formation by 50% under experimental conditions (ED50). The 2-deoxo-5-deazaflavin derivatives, namely 
2a,b,h,j, and 4b exhibited some antiviral activities of 0.8, 20, 4, 20, and 4 µg/mL (ED50), respectively, against 
HSV-1. The obvious antiviral effects are not their actual antiviral potencies but mainly attributed to the pronounced 
cytotoxicities of these compounds.  
The previously reported potent 2-deoxo-2-phenyl-5-deazaflavins,1 which revealed minimum IC50 in the range of 
0.15–0.68 and 0.16–0.72 µg/mL against CCRF-HSB-2 and KB cell lines, respectively, exhibited ca. 3–10 times 
more efficient antitumor activities than those of the aforementioned 2-methylthio-, 2-amino- and 2-(substituted 
amino)-2-deoxo-5-deazaflavins (2–4 and 7), which revealed the minimum IC50 in the range of 1.64–1.96 and 
1.00–1.97 µg/mL against the same cell lines. This can be explained that the phenyl group at the 2-position provide 
better affinity to the enzyme on account of the force of electrostatic attraction between the planar phenyl and the 
target site pocket of the tumor cells. Hence, the phenyl derivatives exhibit a good fitting within the active site and 
better antitumor activity. The SAR revealed that the highest antitumor activities (ca. 2.0 µg/mL) for 
2-deoxo-5-deazaflavins were obtained with the structure features on the pyrimidoquinoline skeleton; SMe, N(Me)2, 
or NH2 group at the C-2 position, Et group at the N-10 position, and Me group at the 7-position, and the moderate 
antitumor activities (ca. 5.0 µg/mL) were obtained with the structure features: HN-C4H7, morpholino or 
4-methylpiperazinyl substituent at the 2-position, Me group at the N-10 position, and 7-OMe, 6,9-(OMe)2, or 
7,8-(Me)2 substituted on the benzene ring. However, the interaction of electrostatic van der Waals attraction for 
these substituents with the active site of enzyme is less than planar phenyl substituent. Therefore, they showed less 
potential affinities and less antitumor activities than the 2-phenyl derivatives. It is noteworthy that 2-amino and 
2-methylthio derivatives (2–4 and 7) exhibited promising antitumour potencies in comparison with the less potent 
2,4-dioxo-5-deazaflavins, which revealed lower activity (IC50 >10 µg/mL) against KB cell line.23  
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2.3. Molecular docking study 
 
Both pharmaceutical companies and university laboratories have been active to develop compounds which can 
inhibit tyrosine kinase activity in the expectation that the potent and selective inhibitors would represent a new 
class of therapeutics for cancers as well as other proliferative diseases. Therefore, PTK inhibitors can be applied 
aptly as a new mode of cancer therapy. Depending on the above mentioned idea, herein we investigated the 
AutoDock binding affinities of the synthesized 2-deoxo-5-deazaflavins (2–7) and computationally designed 
2-deoxo-5-deazaflavins (8a,b) connected with amino acid at the 2-posision into PTK. Towards optimization of the 
aforementioned lead compounds of the promising antitumor activities, the advanced docking program AutoDock 
3.05 24 was used to evaluate the binding free energies as potential inhibitors into the target PTK macromolecule. 
 
2.3.1. Validation of the accuracy and performance of AutoDock. 
 
The most straightforward method for validation of the used scoring function is to inspect how closely the best- 
docked conformation resembles the bound ligand in the experimental crystal structure. As cited in literature,10 if 
the RMSD (root mean square deviation) of the best docked conformation is ≤2.0 Å from the experimental one, the 
used scoring function is successful. Therefore, the validation of the function implemented in AutoDock was done 
by docking of the native ligand into its binding site. The docked results were compared to the crystal structure of 
the bound ligand-protein complex. The obtained success rates of AutoDock24 were highly excellent as shown in 
Figure 3. The STI-571 ligand (Imatinib or Gleevec), 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin- 
3-yl-pyrimidin-2-ylamino)phenyl]-benzamide, was docked into its c-Kit receptor PTK (pdb code: 1t46). 
 
 
  
The RMSD of the docked ligand was 0.25 Å as it seems exactly superimposed on the native bound one. Moreover, 
the obtained binding free energy (ΔGb) was quite low being –18.43 kcal/mol. The docked ligand (yellow stick) 
exhibited hydrogen bonds with almost same atoms of amino acids involved with the native ligand (ball and stick, 
colored by element). The docked STI ligand exhibited three hydrogen bonds between Cys 673, Thr 670, and Asp 
810 amino acids. Whereas, the native ligand exhibited four hydrogen bonds between same three amino acids 
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involved in the docked ligand and another amino acid of Glu 640. These results indicated the high accuracy of the 
AutoDock simulation in comparison with the biological methods.25 
 
2.3.2. AutoDock binding affinities of the synthesized and the designed compounds into PTK 
 
The binding affinity was evaluated by the binding free energies (ΔGb, kcal/mol), inhibition constants (Ki), 
hydrogen bonding, and RMSD values. The compounds which revealed the highest binding affinities, that is, 
lowest binding free energies, within PTK and the hydrogen bond interactions into the target macromolecule are 
represented in Table 2. These compounds include 7-substituted 2-deoxo-10-methyl-2-dimethylamino-5- 
deazaflavins (3d,e), 10-alkyl-2-amino-2-deoxo-5-deazaflavins (4a–c), 2-(substituted amino)-10-alkyl-2-deoxo-5- 
deazaflavins (7c,e,n,p,q), and the computationally designed 2-deoxo-5-deazaflavins connected with amino acids 
(8a,b). The later derivatives exhibited many hydrogen bonds (4–6) between the target PTK. As shown in Table 2, 
compound 8a (ΔGb: –8.88 kcal/mol) exhibited four hydrogen bonds with Thr 670 and RMSD: 5.67 Å, compound 
8b, (ΔGb: –10.63 kcal/mol) exhibited six hydrogen bonds with Lys 623, Val 668, Thr 670, and Asp 810 and 
RMSD: 4.29 Å, compound 7c (ΔGb: –13.37 kcal/mol) exhibited two hydrogen bonds with Ala 621 and Thr 670 
and RMSD: 4.78 Å, compound 7n (ΔGb: –14.50 kcal/mol) exhibited one hydrogen bond with Cys 673 and 
RMSD: 7.93 Å, and compound 7q (ΔGb: –15.05 kcal/mol) exhibited one hydrogen bond with Thr 670 and RMSD: 
3.80 Å. 
 
To investigate the potential PTK inhibition, the comparatively antitumor active 10-alkyl-2-deoxo-2-methylthio-5- 
deazaflavins (2a–j) were also docked into PTK (1t46). Unfortunately, the docking of most compounds (2) was too 
far for the distance (>2.50 Å) between the C4-oxo group and HO of Thr 670 and/or HN of Lys 623 (as common 
hydrogen bond donors) to form the hydrogen bond into the binding site. However, the planar pyrimidoquinoline 
ring was involved in hydrophobic electrostatic surface interaction, where it was sandwiched between the phenyl 
moieties of Phe 811 and Tyr 672 and the terminal hydrocarbon chain of Leu 595 within distance of 3.46, 4.53, and 
3.36 Å, respectively. Also the 2-methylthio group interacts with lys 623, Val 668, and Cys 809 by hydrophobic 
attraction within distance of 3.22, 3.90, and 3.47 Å, respectively. The interactions keep these derivatives in the 
binding site, providing better RMSD values than other derivatives (3.80–5.41 Å). Exceptionally, compounds 2c 
and 2e showed one hydrogen bond between the C4-oxo and HO of Thr 670. This aforementioned docking results 
of 2a–j indicate that these compounds are not expected to be a reasonable candidate for PTK inhibition.  
The molecular docking study revealed that compounds 8a,b prepared by replacement of 2-methylthio moiety of 
10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2) by amino acids such as glycine and histidine exhibited 
reasonable binding energies and more important higher number of hydrogen bonds. The comparative docking 
modes of 8a,b and 7n into c-Kit receptor PTK with its bound ligand STI are shown in Figure 4. The amino acid 
coupled to 5-deazaflavins has been shown to enhance remarkably the binding potentials in PTK. The higher 
affinity of these designed derivatives is presumably attributed to the formation of more hydrogen bonds (4–6 
hydrogen bonds) and/or tighter hydrogen bonds between their 2-amino acid moieties and the binding site. While 
10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2) and other 2-(substituted amino)-2-deoxo-5-deazaflavins (3, 6 
and 7) exhibited less binding affinities into the binding sites of PTK. This may be explained by missing of  
 12 
 
 
substituents at C2-position which provide tight hydrogen bond interaction or surface electrostatic attraction such as 
2-phenyl group as cited in our previous publication.1  
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Figure 5 illustrates docking of compound 4b ( ΔGb: –12.16 kcal/mol) in another region of the binding site along 
with STI-ligand and 4b exhibited one hydrogen bond. Whereas, compounds 7c and 7q were docked in another 
groove with two and one hydrogen bonds, respectively. This different binding mode of these compounds may 
explain their different antiproliferative activity against CCRF-HSB- 2 and KB tumor cell lines as cited in Table 1.   
 
The overall correlation between the growth inhibitory activities (IC50, µg/mL) of the synthesized 5-deazaflavins 
against tumor cells and the binding affinities predicted by AutoDock was fairly good for some compounds. 
Considering the growth inhibition against CCRF-HSB-2 cells, it was noticed that the correlation between IC50 of 
3a,c,d and 7a,b,d,e,h–l,o and their AutoDock binding free energies revealed an excellent correlation coefficient 
(R2) of 0.809 as represented in Figure 6. Whereas, the growth inhibition against KB cells revealed a reasonable 
correlation with AutoDock binding free energies for compounds 3c,d, 4c, and 7a–e,h,i,l of correlation coefficient 
(R2) value of 0.599 as shown in Figure 7. 
 
 
 
 
 
3. Conclusions 
 
In this study, various novel 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2a–j) were synthesized from 
6-(N-monoalkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1a–j) by the reaction using Vilsmeier reagent. The 
similar 2-(substituted amino)-10-alkyl-2-deoxo-5-deazaflavins (3a–e, 6, and 7a–q) were synthesized by the facile 
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replacement of C2-methylthio moiety by amines of different type. 10-Alkyl-2-amino-2-deoxo-5-deazaflavins 
(4a–c) were also prepared in better yield than the published method for compounds 4a,b. Additionally, 
5-deazaflavins {pyrimido[4,5-b]quinolin-2,4-diones} (5a–c) were prepared by acidic hydrolysis of 2-deoxo-2- 
methylthio-5-deazaflavins (2) in good yields. In the growth inhibitory activities of 2–7 against T-cell acute 
lymphoblastoid leukemia cell line (CCRF-HSB-2) and human oral epidermoid carcinoma cell line (KB) in vitro, 
many derivatives showed potential antitumor activities. Among them, compounds 2a,h, 3b and 4b exhibited the 
most significant antiproliferative potencies with IC50 of 1.64–1.96 and 1.00–3.96 µg/mL against CCRF-HSB-2 and 
KB cells, respectively. Some other derivatives, namely 2b,f,i,j, 6, and 7h,m,p showed IC50 of 4.84–7.4 and 
5.42–7.90 µg/mL against CCRF-HSB-2 and KB cells, respectively. These results revealed a promising antitumor 
activity of many derivatives, which are considered as new leads.  
The AutoDock investigation of the synthesized 2-deoxo-5-deazaflavins (2-4, 6 and 7) and the computationally 
designed 2-deoxo-5-deazaflavins connected with amino acids (8a,b) was carried out for lead optimization. Thus, 
they were docked within c-kit protein tyrosine kinase. The overall correlation between the growth inhibitory 
activities (IC50, µg/mL) of the synthesized 5-deazaflavins against tumor cells and the binding affinities predicted 
by AutoDock was fairly good for some compounds, namely, 3a,c,d and 7a,b,d,e,h–l,o against CCRF-HSB-2 cell 
line, with the correlation coefficient (R2) of 0.809. While the correlation between IC50 of compounds 3c,d, 4c, and 
7a–e,h,i,l against KB cell line was also good with the correlation coefficient (R2) of 0.599. Further, in order to 
enhance the binding affinity of these derivatives, 5-deazaflavins connected with amino acids were designed 
computationally. They exhibited preferential binding affinities into PTK with more hydrogen bonding and lower 
binding free energies. These computationally designed hybrid compounds may be promising candidates for 
further antitumor investigation and their syntheses are in progress.  
 
4. Experimental 
4.1. Chemistry 
 
Mps were obtained on a Yanagimoto micro melting point apparatus and are uncorrected. Microanalyses were 
measured by Yanaco CHN Corder MT-5 apparatus. IR spectra were recorded on a JASCO FT/IR-200 
spectrophotometer as Nujol mulls. 1H NMR spectra were obtained using a Varian VXR 300 MHz 
spectrophotometer and chemical shift values were expressed in δ values (ppm) relative to tetramethylsilane (TMS) 
as internal standard. Coupling constants are given in Hz. All NH and OH protons were exchangeable with D2O. 
UV spectra were measured in absolute EtOH using Beckman DU-68S UV spectrophotometer and the wavelength 
value with sh refer to wavelength at which shoulder or inflexion occur in the absorption. All reagents were of 
commercial quality and were used without further purification. Organic solvents were dried in the presence of an 
appropriate drying agent and were stored over suitable molecular sieves. Reaction progress was monitored by 
analytical thin layer chromatography (TLC) on pre-coated glass plates (silica gel 60F254-plate-Merck) and the 
products were visualized by UV light. 
 
4.1.1. General procedure for the preparation of 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones 
(1a–j).  
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A mixture of 6-chloro-2-methylthiopyrimidin-4(3H)-one14,16 (3.0 g, 0.017 mol) and an appropriate N-alkylaniline 
(0.051–0.085 mol) in n-butanol (20 mL) was refluxed with stirring for 12–72 h. After cooling, the precipitated 
solid was filtered off to get the first crop. The filtrate was concentrated in vacuo and the residue was crushed with 
diethyl ether to precipitate powdery crystals, which were filtered off, washed with water, and dried to afford the 
second crop. The collected solids were crystallized from appropriate solvents with charcoal to afford the 
corresponding products as colorless needles in 55–83 % yields. 
 
4.1.2.  6-(N-Methylanilino)-2-methylthiopyrimidin-4(3H)-one (1a).  
Yield, 3.11 g (74%); mp 268–270 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 241 (4.28), 
263sh (4.15), 292sh (3.89); IR (νmax/cm-1): 3220 (NH), 1640 (CO); 1H NMR (CDCl3): δ 2.46 (3H, s, 2-SMe), 3.45 
(3H, s, 6-NMe), 5.06 (1H, s, 5-H), 7.11–7.30 (3H, m, Ph-o,pH), 7.36–7.43 (2H, m, Ph-mH), 13.24 (1H, br s, 3-NH, 
exchangeable with D2O); Anal. calcd for C12H13N3OS: C, 58.28; H, 5.30; N, 16.99. Found C, 58.23; H, 5.43; N, 
16.95. 
 
4.1.3.  6-(N-Ethylanilino)-2-methylthiopyrimidin-4(3H)-one (1b).  
Yield, (2.89 g, 65%); mp 235–236 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 241 (4.56), 
261sh (4.40), 293sh (4.10) ; IR (νmax/cm-1): 3200 (NH), 1640 (CO);  1H NMR (CDCl3): δ 1.20 (3H, t, J = 6.9 Hz, 
6-NCH2-CH3), 2.48 (3H, s, 2-SMe), 3.94 (2H, q, J = 6.9 Hz, 6-NCH2-CH3), 4.90 (1H, s, 5-H), 7.15–7.22 (2H, m, 
Ph-oH), 7.28–7.34 (2H, m, Ph–pH), 7.37–7.45 (2H, m, Ph–mH), 13.35 (1H, br s, 3-NH, exchangeable with D2O); 
Anal. calcd for C13H15N3OS: C, 59.74; H, 5.79; N, 16.08. Found: C, 59.58; H, 5.81; N, 16.10. 
 
4.1.4.  6-(N-Methyl-4-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1c).  
Yield, (3.51 g, 79%); mp 301–303 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 242 (4.56), 
259sh (4.47), 292sh (4.16); IR (νmax/cm-1): 3200 (NH), 1625 (CO); 1H NMR (CDCl3): δ 2.36 (3H, s, pMe), 2.48 
(3H, s, 2-SMe), 3.43 (3H, s, 6-N-Me), 5.02 (1H, s, 5-H), 7.09 (2H, d, J 2',3' = J 5',6' = 8.1 Hz, Ar-oH), 7.19 (2H, d, 
J2',3' = J 5',6' = 8.1 Hz, Ar-mH), 12.94 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C13H15N3OS: C, 
59.74; H, 5.79; N, 16.08 . Found: C, 59.66; H, 5.70; N, 15.86.  
 
4.1.5.  6-(N-Methyl-2-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1d).   
Yield, (2.35 g, 53%); mp 246–248 °C (from MeOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 240 (4.59), 
267sh (4.33), 290sh (4.09); IR (νmax/cm-1): 3200 (NH), 1620 (CO); 1H NMR (CDCl3): δ 2.15 (3H, s, oMe), 2.57 
(3H, br s, 2-SMe), 3.39 (3H, s, 6-NMe), 4.62 (1H, br s, 5-H), 7.08–7.13 (1H, ｍ, Ar-oH), 7.21–7.25 (3H, m, 
Ar-m,pH), 13.07 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C13H15N3OS: C, 59.74; H, 5.74; N, 
16.08. Found: C, 59.72; H, 5.97; N, 15.85.  
 
4.1.6.  6-(N-Methyl-4-methoxyanilino)-2-methylthiopyrimidin-4(3H)-one (1e).  
Yield, (3.58 g, 76%); mp 292–293 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 246 (4.44), 
275sh (4.20), 289sh (4.07); IR (νmax/cm-1): 3200 (NH), 1630 (CO); 1H NMR (CDCl3): δ 2.48 (3H, s, 2-SMe), 3.42 
(3H, s, 6-NMe), 3.82 (3H, s, pOMe), 4.98 (1 H, s, 5-H), 6.91 (2 H, d, J2',3' = J5',6' = 9.0 Hz, Ar-oH), 7.12 (2H, d, J2',3' 
 17 
= J5',6' = 9.0 Hz, Ar-mH), 12.78 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C13H15N3O2S: C, 56.30; 
H, 5.45; N, 15.15. Found: C, 56.13; H, 5.44; N, 15.30. 
  
4.1.7.  6-(N-Methyl-3-methoxyanilino)-2-methylthiopyrimidin-4(3H)-one (1f).   
Yield, (3.54 g, 75%); mp 196–198 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 240 (4.56), 
261sh (4.42), 287sh (4.20); IR (νmax/cm-1): 3200 (NH), 1635 (CO); 1H NMR (CDCl3): δ 2.48 (3H, s, 2-SMe), 3.44 
(3H, s, 6-NMe), 3.80 (3H, s, mOMe), 5.08 (1H, s, 5-H), 6.73–6.77 (1H, m, Ar-pH), 6.78–6.85 (2H, m, Ar-oH), 
7.30 (1H, t, J4',5' = J5',6' = 8.4 Hz, Ar-mH), 13.02 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for 
C13H15N3O2S: C, 56.30; H, 5.45; N, 15.15. Found: C, 56.39; H, 5.48; N, 14.90. 
  
4.1.8.  6-(N-Methyl-4-chloroanilino)-2-methylthiopyrimidin-4(3H)-one (1g).  
Yield, (3.98 g, 83%); mp >300 °C (from MeOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 239 (4.51), 262sh 
(4.43), 291sh (4.21); IR (νmax/cm-1): 3200 (NH), 1620 (CO); 1H NMR (CDCl3): δ 2.44 (3H, s, 2-SMe), 3.41 (3H, s, 
6-NMe), 5.07 (1H, s, 5-H), 6.91 (2H, d, J2',3' = J5',6' = 8.7 Hz, Ar-oH), 7.12 (2H, d, J2',3' = J5',6' = 8.7 Hz, Ar-mH), 
11.89 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C12H12ClN3OS: C, 51.15; H, 4.29; N, 14.91. 
Found: C, 50.85; H, 4.28; N, 14.88. 
  
4.1.9.  6-(N-Ethyl-4-methylanilino)-2-methylthiopyrimidin-4(3H)-one (1h).  
Yield, (2.86 g, 61%); mp 237–239 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 242 (4.63), 
260sh (4.48), 292sh (4.16); IR (νmax/cm-1): 3200 (NH), 1635 (CO); 1H NMR (CDCl3): δ 1.19 (3H, t, J = 7.2 Hz, 
6-NCH2-CH3 ), 2.37 (3H, s, pMe), 2.49 (3H, s, 2-SMe), 3.91 (2H, q, J = 7.2 Hz, 6-NCH2-CH3), 4.86 (1H, s, 5-H), 
7.04 (2H, d, J2',3' = J5',6' = 8.4 Hz, Ar-oH), 7.19 (2H, d, J2',3' = J5',6' = 8.4 Hz, Ar-mH), 13.13 (1H, br s, 3-NH, 
exchangeable with D2O); Anal. calcd for C14H17N3OS: C, 61.06; H, 6.22; N, 15.26. Found: C, 61.12; H, 6.24; N, 
15.50.  
 
4.1.10.  6-(N-Methyl-3,4-dimethylanilino)-2-methylthiopyrimidin-4(3H)-one (1i).   
Yield, (3.65 g, 78%); mp 281–283 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 243 (4.55), 
260sh (4.44), 292sh (4.13); IR (νmax/cm-1): 3200 (NH), 1625 (CO); 1H NMR (CDCl3): δ 2.25 (3H, s, pMe), 2.26 
(3H, s, mMe), 2.49 (3H, s, 2-SMe), 3.42 (3H, s, 6-NMe), 5.00 (1H, s, 5-H), 6.92 (1H, dd, J5',6' = 7.8 Hz, J2',6' = 1.5 
Hz , N-Ar-6’H), 6.98 (1H, d, J2',6' = 1.5 Hz, Ar-2’H), 7.14 (1H, d, J5',6' = 7.8 Hz, Ar-5’H), 12.74 (1H, br s, 3-NH, 
exchangeable with D2O); Anal. calcd for C14H17N3OS: C, 61.06; H, 6.22; N, 15.26. Found: C, 61.13; H, 6.17; N, 
14.95.  
 
4.1.11.  6-(N-Methyl-2,5-dimethoxyanilino)-2-methylthiopyrimidin-4(3H)-one (1j).   
Yield, (3.76 g, 72%); mp 227–229 °C (from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 240 (4.50), 
266sh (4.23), 292sh (4.16); IR (νmax/cm-1): 3200 (NH), 1630 (CO); 1H NMR (CDCl3): δ 2.50 (3H, br s, 2-SMe), 
3.36 (3H, s, 6-NMe), 3.75 (3H, s, 2'-OMe), 3.76 (3H, s, 5'-OMe), 4.87 (1H, s, 5-H), 6.73 (1H, d, J4',6' = 3.0 Hz, 
Ar-6’-H), 6.83 (1H, dd, J3',4' = 9.0 Hz, J4',6' = 3.0 Hz, Ar-4’H), 6.90 (1H, d, J3',4' = 9.0 Hz, Ar-3’H), 12.93 (1H, br s, 
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3-NH, exchangeable with D2O); Anal. calcd for C14H17N3O3S: C, 54.71; H, 5.57; N, 13.67. Found: C, 54.81; H, 
5.62; N, 13.39.  
 
4.1.12.  General procedure for the preparation of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins 
{10-alkyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-ones} (2a–j).  
A mixture of 6-(N-alkylanilino)-2-methylthiopyrimidin-4(3H)-ones (1, 0.01 mol) and phosphoryl chloride (7.7 g, 
0.05 mol) in anhydrous dimethylformamide (10 mL) was heated under stirring at 90 °C for 0.5–2 h. Then, the 
reaction mixture was poured onto ice and neutralized with aqueous ammonia (pH 7). The yellow crystals 
separated were filtered off, washed with water, dried and recrystallized from an appropriate solvent to afford the 
corresponding product as yellow needles in 71–99 % yields. 
 
4.1.13.  10-Methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2a).   
Yield, (2.55 g, 99%); mp 281–282 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 
(4.57), 268 (4.24), 286 (4.42), 340 (4.12), 423 (4.17); IR (νmax/cm-1): 1655 (CO); 1H NMR (CDCl3): δ 2.62 (3H, s, 
2-SMe), 4.29 (3H, s, 10-Me), 7.60 (1H, t, J6,7 = J7,8 = 8.7 Hz, 7-H), 7.81 (1H, d, J8,9 = 8.7 Hz, 9-H), 7.97 (1H, t, J7,8 
= J8,9 = 8.7 Hz, 8-H), 7.02 (1H, d, J6,7 = 8.7 Hz, 6-H), 9.24 (1H, s, 5-H); Anal. calcd for C13H11N3OS: C, 60.68; H, 
4.31; N, 16.33. Found: C, 60.30; H, 4.53; N, 15.94.  
 
4.1.14.  10-Ethyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2b).   
Yield, (2.69 g, 99%); mp 262–265 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 
(4.64), 268sh (4.32), 286 (4.49), 338 (4.19), 424 (4.25); IR (νmax/cm-1): 1655 (CO); 1H NMR (CDCl3): δ 1.54 (3H, 
t, J = 6.9 Hz, 10-CH2-CH3), 2.63 (3H, s, 2-SMe), 4.96 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 7.59 (1H, dt, 1 H, J6,7 = 
J7,8 = 9.0 Hz, J7,9 = 1.5 Hz, 7-H), 7.82 (1H, d, J8,9 = 9.0 Hz, 9-H), 7.97 (1H, dt, J7,8 = J8,9 = 9.0 Hz, J6,8 = 1.5 Hz, 
8-H), 8.04 (1H, dd, J6,7 = 9.0 Hz, J6,8 = 1.5 Hz, 6-H), 9.24 (1H, s, 5-H); Anal. calcd for C14H13N3OS: C, 61.97; H, 
4.83; N, 15.49. Found: C, 62.08; H, 5.01; N, 15.12. 
  
4.1.15.  7,10-Dimethyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2c).   
Yield, (2.66 g, 98%); mp 279–281 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 
(4.62), 270 (4.36), 288 (4.46), 340 (4.19), 432 (4.23); IR (νmax/cm-1): 1640 (CO); 1H NMR (CDCl3): δ 2.56 (3H, s, 
7-Me), 2.62 (3H, s, 2-SMe), 4.28 (3H, s, 10-Me), 7.71 (1H, d, J8,9 = 8.7 Hz, 9-H), 7.75–7.80 (1H, m, 8-H), 7.81 
(1H, d, J6,8 = 2.1 Hz, 6-H), 9.16（1H, s, 5-H）; Anal. calcd for C14H13N3OS: C, 61.97; H, 4.83; N, 15.49. Found: C, 
61.66; H, 4.89; N, 15.27.  
 
4.1.16.  9,10-Dimethyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2d).   
Yield, (1.93 g, 71%); mp 273–274 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 227 
(4.56), 270 (4.36), 290 (4.52), 351 (4.26), 429 (4.21); IR (νmax/cm-1): 1650 (CO); 1H NMR (CDCl3): δ 2.63 (3H, s, 
2-SMe), 2.91 (3H, s, 9-Me), 4.35 (3H, s, 10-Me), 7.45 (1H, t, J6,7 = J7,8 = 7.5 Hz, 7-H), 7.70–7.76 (1H, m, 8-H), 
7.82 (1H, d, J6,7 = 7.5 Hz, 6-H), 9.14 (1H, s, 5-H); Anal. calcd for C14H13N3OS: C, 61.97; H, 4.83; N, 15.49. 
Found: C, 61.73; H, 4.96; N, 15.10. 
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4.1.17.  7-Methoxy-10-methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2e).   
Yield, (2.7 g, 94%); mp 275–277 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 229 
(4.48), 275 (4.40), 290 (4.43), 339 (4.12), 450 (4.19); IR (νmax/cm-1): 1650 (CO); 1H NMR (CDCl3): δ 2.63 (3H, s, 
2-SMe), 3.97 (3H , s, 7-OMe), 4.31 (3H, s, 10-Me), 7.31 (1H, d, J6,8 = 3.0 Hz, 6-H), 7.61 (1H, dd, J8,9 = 9.3 Hz, J6,8 
= 3.0 Hz, 8-H), 7.77 (1H, d, J8,9 = 9.3 Hz, 9-H), 9.19 (1H, s, 5-H); Anal. calcd for C14H13N3O2S: C, 58.52; H, 4.56; 
N, 14.62. Found: C, 58.26; H, 4.67; N, 14.22.  
 
4.1.18.  8-Methoxy-10-methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2f).   
Yield, (2.70 g, 94%); mp 285–287 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 231 
(4.60), 256 (4.25), 281 (4.44), 359 (4.05), 417 (4.47); IR (νmax/cm-1): 1630 (CO); 1H NMR (CDCl3): δ 2.60 (3H, s, 
2-SMe), 4.07 (3H, s, 8-OMe), 4.21 (3H, s, 10-Me), 7.03 (1H, d, J7,9 = 2.4 Hz, 9-H), 7.18 (1H, dd, J6,7 = 9.0 Hz, J7,9 
= 2.4 Hz, 7-H), 7.89 (1H, d, J6,7 = 9.0 Hz, 6-H), 9.09 (1H, s, 5-H); Anal. calcd for C14H13N3O2S: C, 58.52; H, 4.56; 
N, 14.62. Found: C, 58.42; H, 4.63; N, 14.36.  
 
4.1.19.  7-Chloro-10-methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2g).   
Yield, (2.86 g, 98%); mp 287–289 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 227 
(4.63), 272 (4.49), 291 (4.46), 332 (4.12), 434 (4.19); IR (νmax/cm-1): 1650 (CO); 1H NMR (CDCl3): δ 2.62 (3H, s, 
2-SMe), 4.27 (3H, s, 10-Me), 7.75 (1H, d, J8,9 = 9.3 Hz, 9-H), 7.61 (1H, dd, J8,9 = 9.3 Hz, J6,8 = 2.4 Hz, 8-H), 7.97 
(1H, d, J6,8 = 2.4 Hz, 6-H), 9.12 (1H, s, 5-H); Anal. calcd for C13H10ClN3OS: C, 53.52; H, 3.45; N, 14.40. Found: 
C, 53.55; H, 3.66; N, 14.17.  
 
4.1.20.  10-Ethyl-7-methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2h).   
Yield, (2.71 g, 95%); mp 278–280 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 
(4.65), 269 (4.41), 289 (4.49), 340 (4.23), 432 (4.26); IR (νmax/cm-1): 1655 (CO); 1H NMR (CDCl3): δ 1.52 (3H, t, 
J = 7.2 Hz, 10-CH2-CH3 ), 2.56 (3H, s, 7-Me), 2.62 (3H, s, 2-SMe), 4.94 (2H, q, J = 7.2 Hz, 10-CH2-CH3), 
7.69–7.74 (1H, m, 9-H), 7.76–7.81 (3H, m, 6, 8-H), 9.17 (1H, s, 5-H); Anal. calcd for C15H15N3OS: C, 63.13; H, 
5.30; N, 14.73. Found: C, 63.37; H, 5.55; N, 14.51.  
 
4.1.21.  7,8,10-Trimethyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2i).   
Yield, (2.31 g, 81%); mp 266–268 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 
(4.65), 270 sh (4.35), 284 (4.48), 351 (4.23), 430 (4.30); IR (νmax/cm-1): 1655 (CO); 1H NMR (CDCl3): δ 2.46 (3H, 
s, 7-Me), 2.57 (3H, s, 8-Me), 2.62 (3H, s, 2-SMe), 4.26  (3H, s, 10-Me), 7.56 (1H, s, 9-H), 7.70 (1H, s, 6-H), 
9.13 (1H, s, 5-H); Anal. calcd for C15H15N3OS: C, 63.13; H, 5.30; N, 14.72. Found: C, 62.83; H, 5.42; N, 14.32. 
  
4.1.22.  6,9-Dimethoxy-10-methyl-2-methylthiopyrimido[4,5-b]quinolin-4(10H)-one (2j).  
Yield, (2.73 g, 86%); mp 251–253 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 213 
(4.31), 259 (4.26), 278 sh (4.09), 311 (4.41), 403 (4.33); IR (νmax/cm-1): 1660 (CO); 1H NMR (CDCl3): δ 2.63 (3H, 
s, 2-SMe), 3.96 (3H, s, 9-OMe), 3.98 (3H, s, 6-OMe), 4.48 (3H, s, 10-Me), 6.78 (1H, d, J7,8 = 9.0 Hz, 7-H), 7.31 
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(1H, d, J8,9 = 9.0 Hz, 8-H), 9.63 (1H, s, 5-H); Anal. calcd for C15H15N3O3S: C, 56.77; H, 4.76; N, 13.24. Found: C, 
56.65; H, 4.78; N, 13.01.  
 
4.1.23.  General procedure for the preparation of 10-alkyl-2-deoxo-2-dimethylamino-5-deazaflavins 
{10-alkyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-ones} (3a–e)  
A mixture of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavin (2, 5.0 mmol) and 50% aqueous dimethylamine (50 
mL) was heated in steel sealed tube at 135 °C (10 kg/cm2 pressure) for 4 h. After the reaction was complete, the 
precipitated crystals were collected by filteration, and mother liquid was evaporated in vacuo to get the second 
crop. The product was washed with water, dried and recrystallized from an appropriate solvent to afford the 
corresponding product as yellow crystals in 59–96% yields. 
 
4.1.24.  10-Methyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-one (3a).  
Yield, (1.22 g, 96%); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.65), 271 
(4.68), 279sh (4.57), 320 (4.12), 382sh (4.15), 408 (4.33), 432 (4.28); IR (νmax/cm-1): 1655 (CO); 1H NMR 
(CDCl3): δ 3.34 (6H, s, 2-N(CH3)2 ), 4.12 (3H, s,10-Me), 7.44 (1H, t, J6,7 = J7,8 = 7.8 Hz, 7-H), 7.65 (1H, d, J8,9 = 
8.7 Hz, 9-H), 7.81 (1H, t, J7,8 = 7.8 Hz, J8,9 = 8.7 Hz, 8-H), 7.86 (1H, d, J6,7 = 7.8 Hz, 6-H), 8.94 (1H, s, 5-H); Anal. 
calcd for C14H14N4O· 0.1H2O: C, 65.66; H, 5.59; N, 21.88. Found: C, 65.55; H, 5.80; N, 21.50.  
 
4.1.25.  10-Ethyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-one (3b).  
Yield, (0.79 g, 59.%); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 (4.55), 271 
(4.53), 278sh (4.48), 322 (3.96), 383sh (4.04), 407 (4.22), 431 (4.16); IR (νmax/cm-1): 1650 (CO); 1H NMR 
(CDCl3): δ 1.49 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 3.34 (3H, s, 2-NMe), 3.48 (3H, s, 2-NMe), 4.79 (2H, q, J = 7.2 
Hz, 10-CH2-CH3), 7.43 (1H, dt, J6,7 = J7,8 = 7.8 Hz, J7,9 = 1.8 Hz, 7-H), 7.65 (1H, d, J8,9 = 8.7 Hz, 9-H), 7.81 (1H, dt, 
J7,8 = 7.8 Hz, J8,9 = 8.7 Hz, J6,8 = 1.8 Hz, 8-H), 7.90 (1H, dd, J6,7 = 7.8 Hz, J6,8 = 1.8 Hz, 6-H), 8.95 (1H, s, 5-H); 
Anal. calcd for C15H16N4O: C, 67.15; H, 6.01; N, 20.88. Found: C, 66.86; H, 6.12; N, 20.70.  
 
4.1.26.  7-Methoxy-10-methyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-one (3c). 
Yield, (1.24 g, 87%); mp 291–294 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 
(4.64), 279 (4.69), 326 (4.18), 400sh (4.09), 428 (4.37), 454 (4.36); IR (νmax/cm-1): 1660 (CO); 1H NMR (CDCl3): 
δ 3.33 (6H, s, 2-N(CH3)2), 3.92 (3H, s, 7-OMe), 4.12 (3H, s,10-Me), 7.20 (1H, d, J6,8 = 3.0 Hz, 6-H), 7.44 (1H, dd, 
J8,9 = 9.3 Hz, J6,8 = 3.0 Hz, 8-H), 7.60 (1H, d, J8,9 = 9.3 Hz, 9-H), 8.88 (1H, s, 5-H); Anal. calcd for C15H16N4O2: C, 
63.37; H, 5.67; N, 19.71. Found: C, 63.03; H, 5.65; N, 19.52.  
 
4.1.27.  7-Chloro-10-methyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-one (3d). 
Yield, (0.94 g, 65%); mp 291–293 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 
(4.64), 275 (4.70), 286sh (4.52), 318 (4.06), 390sh (4.10), 415 (4.25), 424 (4.19); IR (νmax/cm-1): 1650 (CO); 1H 
NMR (CDCl3): δ 3.33 (3H, s, 2-NMe), 3.34 (3H, s, 2-NMe), 4.09 (3H, s,10-Me), 7.59 (1H, d, J8,9 = 9.0 Hz, 9-H), 
7.74 (1H, dd, J8 9 = 9.0 Hz, J6,8 = 2.4 Hz, 8-H), 7.80 (1H, d, J6,8 = 2.4 Hz, 6-H), 8.81 (1H, s, 5-H); Anal. calcd for 
C14H13ClN4O· 0.2H2O: C, 57.52; H, 4.62; N, 19.17. Found: C, 57.40; H, 4.60; N, 19.07.  
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4.1.28.  7,10-Dimethyl-2-dimethylaminopyrimido[4,5-b]quinolin-4(10H)-one (3e). 
Yield, (1.15 g, 86%); mp >300 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 (4.68), 
273 (4.68), 281sh (4.59), 323 (4.13), 389sh (4.15), 413 (4.35), 438 (4.30); IR (νmax/cm-1): 1655 (CO); 1H NMR 
(CDCl3): δ 2.50 (3H, s, 7-Me), 3.33 (6H, s, 2-NMe2), 4.10 (3H, s,10-Me), 7.55 (1H, d, J8,9 = 9.6 Hz, 9-H), 
7.61–7.65 (2H, m, 6 and 8-H), 8.88 (1H, s, 5-H); Anal. calcd for C15H16N4O: C, 67.15; H, 6.01; N, 20.88. Found: 
C, 66.92; H, 6.09; N, 20.88.  
 
4.1.29.  General procedure for the preparation of 10-alkyl-2-amino-2-deoxo-5-deazflavins 
{10-alkyl-2-aminopyrimido[4,5-b]quinolin-4(10H)-ones} (4a-c) 
A mixture of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2, 4.0 mmol) and ammonium acetate (10 g, 0.13 
mol) was heated under stirring at 160–165 °C for 0.5–3 h. The reaction mixture was cooled, diluted with water (15 
mL), neutralized with aqueous ammonia (pH 7), and cooled in refrigerator overnight. The resulting yellow 
crystals were collected by filtration, dried and crystallized from an appropriate solvent to give the corresponding 
products as yellow needles in 57–77% yields. 
 
4.1.30.  2-Amino-10-methylpyrimido[4,5-b]quinolin-4(10H)-one (4a) 
Yield, (0.64 g, 57%); mp 284–288 °C (decomp., from DMF, lit.,26 288 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 
cm–1): 218 (4.40), 267 (4.44), 319 (3.95), 380sh (3.67), 401 (3.83), 425 (3.72); IR (νmax/cm-1): 3340 and 3470 
(NH), 1640 (CO); 1H NMR (CDCl3): δ 4.18 (3H, s,10-NMe), 5.38 (1H, br s, 2-NH, exchangeable with D2O), 5.74 
(1H, br s, 2-NH, exchangeable with D2O), 7.43 (1H, dt, J6,7 = J7,8 = 7.8 Hz, J7,9 = 1.5 Hz, 7-H), 7.71 (1H, d, J8,9 = 
8.7 Hz, 9-H), 7.88 (1H, dt, J7,8 = 7.8 Hz, J8,9 = 8.7 Hz, J6,8 = 1.5 Hz, 8-H), 7.90 (1H, dd, J6,7 = 7.8 Hz, J6,8 = 1.5 Hz, 
6-H), 9.06 (1H, s, 5-H); Anal. calcd for C12H10N4O· 0.3H2O: C, 62.22; H, 4.61; N, 24.19. Found: C, 62.35; H, 
4.65; N, 23.78.  
 
4.1.31.  2-Amino-10-ethylpyrimido[4,5-b]quinolin-4(10H)-one (4b) 
Yield, (0.93 g, 77%); mp 264–266 °C (from EtOH, lit.,26 266 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 
220 (4.56), 268 (4.63), 319 (4.09), 378sh (3.83), 400 (4.02), 424 (3.91); IR (νmax/cm-1): 3320 and 3410 (NH), 1630 
(CO); 1H NMR [(CD3)2SO]: δ 1.36 (3H, t, J = 6.9 Hz, 10-CH2-CH3), 4.81 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 7.38 
(2H, br s, 2-NH2, exchangeable with D2O), 7.54 (1H, dt, J6,7 = J7,8 = 7.8 Hz, J7,9 = 1.2 Hz, 7-H), 7.88–8.06 (2H, m, 
8 and 9-H), 8.20 (1H, dd, J6,7 = 7.8 Hz, J6,8 = 1.2 Hz, 6-H), 8.92 (1H, s, 5-H); Anal. calcd for C13H12N4O· H2O: C, 
60.45; H, 5.46; N, 21.69. Found: C, 60.28; H, 5.49; N, 21.29. 
  
4.1.32.  2-Amino-7,10-dimethylpyrimido[4,5-b]quinolin-4(10H)-one (4c). 
Yield, (1.02 g, 85 %); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.57), 268 
(4.66), 320 (4.08), 381sh (3.96), 408 (4.11), 428 (4.02); IR (νmax/cm-1): 3360 and 3330 (NH), 1635 (CO); 1H NMR 
[(CD3)2SO]: δ 2.47 (3H, s, 7-Me), 4.09 (3H, s, 10-Me), 7.15 (2H, br s, 2-NH2, exchangeable with D2O), 7.75 (1H, 
dd, J8,9 = 9.0 Hz, J6,8 = 2.1 Hz, 8-H), 7.82 (1H, d, J8,9 = 9.0 Hz, 9-H), 7.94 (1H, br s, 6-H), 8.79 (1H, s, 5-H).; Anal. 
calcd for C13H12N4O· 0.3H2O: C, 63.56; H, 5.17; N, 22.81. Found: C, 63.96; H, 5.34; N, 22.44.  
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4.1.33.  General procedure for the preparation of 10-alkyl-5-deazaflavins {10-alkylpyrimido[4,5-b] 
quinoline-2,4(3H,10H)-diones} (5) 
To 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2, 0.01 mol) was added 5N hydrochloric acid (250 mL). Then, 
the mixture was refluxed for 1–2 h and the resulting clear yellow solution was concentrated in vacuo. The yellow 
residue was crushed with water and neutralized with aqueous ammonia (pH 7). The precipitated powdery crystals 
were filtered off, washed well with water, dried and recrystallized from glacial acetic acid to afford the 
corresponding products as yellow needles in 78–91% yields. 
 
4.1.34.  10-Methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione (5a) 
Yield, (2.07 g, 91%); mp >300 °C (from HOAc, lit.,27 359 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 218 
(4.57), 261 (4.55), 318 (3.97), 398 (4.04), 420 (3.88); IR (νmax/cm-1): 3140 (NH), 1700 and 1660 (CO); 1H NMR 
[(CD3)2SO]: δ 4.04 (3H, s, 10-Me), 7.48–7.61 (1H, br m, 7-H), 7.86–8.03 (2H, br m, 8 and 9-H), 8.18 (1H, br d, 
J6,7 = 7.2 Hz, 6-H), 9.0 (1H, s, 5-H), 11.06 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C12H9N3O2· 
0.2H2O: C, 62.44; H, 4.10; N, 18.20. Found: C, 62.16; H, 4.24; N, 17.92.  
 
4.1.35.  10-Ethylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione (5b) 
Yield, (2.20 g, 91%); mp >300 °C (from HOAc, lit.,27 353 °C); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 
(4.43), 262 (4.65), 319 (4.05), 396 (3.17), 417 (4.06); IR (νmax/cm-1): 3140 (NH), 1700 and 1660 (CO); 1H NMR 
[(CD3)2SO]: δ 1.34 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 4.74 (2H, q, J = 7.2 Hz, 10-CH2-CH3), 7.54 (1H, dt, J6,7 = J7,8 
= 8.1 Hz, J7,9 = 2.4 Hz, 7-H), 7.92–8.01 (2H, m, 8 and 9-H), 8.19 (1H, br d, J6,7 = 8.1 Hz, 6-H), 9.0 (1H, s, 5-H), 
11.08 (1H, br s, 3-NH, exchangeable with D2O); Anal. calcd for C13H11N3O2: C, 64.72; H, 4.60; N, 17.42. Found: 
C, 64.88; H, 4.85; N, 17.05.  
 
4.1.36.  7-Methoxy-10-methylpyrimido[4,5-b]quinoline-2,4(3H,10H)-dione (5c) 
Yield, (2.01 g, 91%); mp >300 °C (from HOAc); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (4.69), 262 
(4.77), 324 (4.39), 426 (4.41), 447 (4.40); IR (νmax/cm-1): 3140 (NH), 1700 and 1655 (CO); 1H NMR [(CD3)2SO]: 
δ 3.91 (3H, s, 7-OMe), 4.05 (3H, s, 10-Me), 7.59 (1H, dd, J6,8 = 2.7 Hz, J8,9 = 8.7 Hz, 8-H), 7.70 (1H, d, J6,8 = 2.7 
Hz, 6-H), 7.87 (1H, d, J8,9 = 8.7 Hz, 9-H), 8.90 (1H, s, 5-H), 10.65 (1H, br s, 3-NH, exchangeable with D2O); Anal. 
calcd for C13H11N3O3· 0.1H2O: C, 60.27; H, 4.36; N, 16.22. Found: C, 60.25; H, 4.68; N, 15.83.  
 
4.1.37.  Preparation of 2-n-butylamino-10-methylpyrimido[4,5-b]quinolin-4-(10H)-one (6). 
n-Butylammonium acetate was prepared in situ by slowly adding glacial acetic acid (5.7 mL, 0.1 mol) to 
n-butylamine (7.31g, 0.1 mol) in an ice bath. 2-Deoxo-10-methyl-2-methylthio-5-deazaflavin (2, 0.008 mol) was 
added to the n-butylammonium acetate and the mixture was fused under stirring at 150–165 °C for 1–3 h. After 
the reaction was complete, water (100 mL) was added to the mixture to give a turbid solution. The residue 
concentrated in vacuo was dissolved in hot water and brought to pH 8 with sodium bicarbonate to give a yellow 
crystalline solid, which was dried and recrystallized from DMF to afford yellow needles. 
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Yield, (1.28 g, 91%); mp 252–254 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 219 
(4.59), 269 (4.63), 273sh (4.60), 321 (4.08), 403 (4.13), 422sh (4.07); IR (νmax/cm-1): 3180 (NH), 1655 (CO); 1H 
NMR [(CD3)2SO]: at 100 °C: δ 0.93 (3H, t, J = 7.2 Hz, 2-N(CH2)3-CH3), 1.39 (2H, sextet, J = 7.2 Hz, 
2-N(CH2)2-CH2-CH3), 1.59 (2H, quintet, J = 7.2 Hz, 2-NCH2-CH2-CH2-CH3), 3.30–3.55 (2H, m, 
2-NCH2-(CH2)2-CH3), 4.07 (3H, s, 10-Me), 7.14 (1H, br s, 2-NH, exchangeable with D2O), 7.45–7.55 (1H, m, 
9-H), 7.78–7.87 (2H, m, 7 and 8-H), 8.06 (1H, br d, J = 7.8 Hz, 6-H), 8.77 (1H, s, 5-H); Anal. calcd for 
C16H18N4O· 0.4H2O: C, 66.37; H, 6.54; N, 19.35. Found: C, 66.04; H, 6.52; N, 19.17.  
 
4.1.38.  General procedure for the preparation of 2-(substituted amino)-10-alkyl-2-deoxo-5-deazaflavins  
{2-(substituted amino)-10-alkylpyrimido[4,5-b]quinolin-4(10H)-ones} (7a–q) 
A mixture of 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2, 5.0 mmol) and an appropriate primary or 
secondary amine (25–35 mmol) in n-butanol (30 mL) was refluxed with stirring for 2–5 h. After the clear yellow 
solution was kept overnight in refrigerator, the precipitated yellow crystalline solid was collected by filtration to 
get the first crop. The filtrate was concentrated in vacuo and the residue was treated with appropriate solvent, such 
as water or ethanol for the piperidine, morpholine, N-(2-hydroxyethyl)-N-methylamine, and N-methylpiperazine 
derivatives and petroleum ether for the n-octylamine derivative, to get the second crop of the crude product of free 
from amines. The collected solids were dried and recrystallized from an appropriate solvent to give the 
corresponding products as bright yellow needles in 70–99% yields. 
 
4.1.39.  2-[N-(2-Hydroxyethyl)-N-methylamino]-10-methylpyrimido[4,5-b]quinolin-4(10H)-one (7a). 
Yield, (1.11 g, 78%); mp 251–253 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 
(4.51), 272 (4.49), 278sh (4.45), 321 (3.92), 383sh (4.00), 408 (4.18), 431 (4.12); IR (νmax/cm-1): 3260 (OH), 1650 
(CO); 1H NMR (CDCl3): δ 2.01 (1H, br s, OH, exchangeable with D2O), 3.39 (3H, s, 2-NMe), 3.96 (4H, br s, 
2-N-CH2-CH2), 4.12 (3H, s, 10-Me), 7.44 (1H, t, J6,7 = J7,8 = 8.1 Hz, 7-H), 7.65 (1H, d, J8,9 = 8.1 Hz, 9-H), 7.82 
(1H, t, J7,8 = J8,9 = 8.1 Hz, 8-H), 7.89 (1H, d, J6,7 = 8.1 Hz, 6-H), 8.95 (1H, s, 5-H); Anal. calcd for C15H16N4O2· 
0.4H2O: C, 61.80; H, 5.81; N, 19.22. Found: C, 61.93; H, 5.71; N, 18.91.  
 
4.1.40.  10-Ethyl-2-[N-(2-hydroxyethyl)-N-methylamino]pyrimido[4,5-b]quinolin-4-(10H)-one (7b). 
Yield, (1.19 g , 80%); mp 250–252 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.72), 271 
(4.68), 279sh (4.63), 319 (4.12), 384sh (4.22), 408 (4.39), 432 (4.32); IR (νmax/cm-1): 3260 (OH), 1650 (CO); 1H 
NMR (CDCl3): δ 1.51 (3H, t, J = 6.9 Hz, 10-CH2-CH3), 1.81 (1H, br s, OH, exchangeable with D2O), 3.40 (3H, s, 
2-NMe), 3.93–3.99 (4H, m, 2-NCH2-CH2-), 4.80 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 7.47 (1H, t, J6,7 = J7,8 = 7.8 Hz, 
7-H), 7.68 (1H, d, J8,9 = 7.8 Hz, 9-H), 7.85 (1H, dt, J7,8 = J8,9 = 7.8 Hz, J6,8 = 1.5 Hz, 8-H), 7.93 (1H, d, J6,7 = 7.8 Hz, 
6-H), 8.97 (1H, s, 5-H); Anal. calcd for C16H18N4O2: C, 64.41; H, 6.08; N, 18.78. Found: C, 64.13; H, 6.06; N, 
18.50. 
 
4.1.41.  10-Ethyl-2-[N-(2-hydroxyethyl)-N-methylamino]-7-methylpyrimido[4,5-b]quinolin-4-(10H)-one 
(7c) 
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Yield, (1.16 g, 74%); mp 272–274 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 224 
(4.64), 274 (4.62), 282sh (4.53), 325 (4.09), 387sh (4.09), 414 (4.30), 438 (4.26); IR (νmax/cm-1): 3210 (OH), 1650 
(CO); 1H NMR (CDCl3): δ 1.31 (3H, t, J = 6.9 Hz, 10-CH2-CH3), 1.81 (1H, br s, OH, exchangeable with D2O), 
2.51 (3H, s, 7-Me), 3.39 (3H, s, 2-NMe), 3.96 (4H, br s, 2-NCH2-CH2-), 4.77 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 
7.54–7.61 (2H, m, 6 and 8-H), 7.66 (1H, d, J8,9 = 8.1 Hz, 9-H), 8.91 (1H, s, 5-H); Anal. calcd for C17H20N4O2: C, 
65.37; H, 6.45; N, 17.94. Found: C, 65.21; H, 6.46; N, 17.84.  
  
4.1.42.  2-[N-(2-Hydroxyethyl)-N-methylamino]-8-methoxy-10-methylpyrimido[4,5-b]quinolin-4(10H)-one 
(7d). 
Yield, (1.19 g, 76%); mp 288–291 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 230 
(4.69), 269 (4.53), 274sh (4.50), 354sh (4.04), 380sh (4.18), 401 (4.46), 423 (4.50); IR (νmax/cm-1): 3200 (OH), 
1645 (CO); 1H NMR (CDCl3): δ 3.31 (3H, s, 2-NMe), 3.58–3.74 (2H, m, 2-N-CH2-CH2), 3.75–3.84 (2H, m, 
2-N-CH2-CH2), 4.00 (3H, s, 8-OMe), 4.09 (3H, s,10-Me), 4.64 (1H, br s, OH, exchangeable with D2O), 7.15 (1H, 
br d, J6,7 = 8.4 Hz, 7-H), 7.24 (1 H, br s, 9-H), 8.06 (1H, d, J6,7 = 8.4 Hz, 6-H), 8.78 (1H, s, 5-H); Anal. calcd for 
C16H18N4O3.0.1H2O: C, 60.79; H, 5.80; N, 17.72. Found: C, 60.72; H, 5.77; N, 17.65. 
 
4.1.43.  10-Methyl-2-piperidinopyrimido[4,5-b]quinolin-4(10H)-one (7e). 
Yield, (1.19 g, 81%); mp 275–277 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 (4.62), 273 
(4.62), 278sh (4.60), 320 (4.03), 384sh (4.15), 410 (4.31), 434 (4.24);  IR (νmax/cm-1): 1660 (CO); 1H NMR 
(CDCl3): δ 1.68 (6H, br s, 3’, 4’ and 5’-CH2), 3.98–4.07 (4H, m, 2’ and 6’-CH2), 4.11 (3H, s, 10-Me), 7.44 (1H, dt, 
J6,7 = 8.7 Hz, J7,8 = 7.8 Hz, J7,9 = 1.5 Hz, 7-H), 7.64 (1H, d, J8,9 = 8.7 Hz, 9-H), 7.80 (1H, dt, J7,8 = 7.8 Hz J8,9 = 8.7 
Hz, J6,8 = 1.5 Hz, 8-H), 7.87 (1H, dd, J6,7 = 8.7 Hz, J6,8 = 1.5 Hz, 6-H), 8.93 (1H, s, 5-H); Anal. calcd for 
C17H18N4O· 0.1H2O: C, 68.94; H, 6.19; N, 18.92. Found: C, 68.66; H, 6.17; N, 18.89.  
 
4.1.44.  7-Chloro-10-methyl-2-morpholinopyrimido[4,5-b]quinolin-4(10H)-one (7f). 
Yield, (1.29 g, 78%), mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (4.65), 276 
(4.61), 286sh (4.53), 319 (4.02), 392sh (4.07), 416 (4.23), 441 (4.19); IR (νmax/cm-1): 1660 (CO); 1H NMR 
(CDCl3): δ 3.73–3.82 (4H, m, 2’ and 6’-NCH2), 4.03-4.15 (4H, m, 3’ and 5’-OCH2), 4.11 (3H, s, 10-Me), 7.61 
(1H, d, J8,9 = 9.0 Hz, 9-H), 7.77 (1H, dd, J8,9 = 9.0 Hz, J6,8 = 2.4 Hz, 8-H), 7.85 (1H, d, J6,8 = 2.4 Hz, 6-H), 8.87 (1H, 
s, 5-H); Anal. calcd for C16H15ClN4O2· 0.4H2O: C, 56.86; H, 4.71; N, 16.58. Found: C, 56.86; H, 4.61; N, 16.24.  
 
4.1.45.  10-Methyl-2-morpholinopyrimido[4,5-b]quinolin-4-(10H)-one (7g). 
Yield, (1.47 g, 99%); mp 296–298 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 
(4.63), 272 (4.60), 279sh (4.55), 319 (4.07), 383sh (4.08), 406 (4.26), 431 (4.20); IR (νmax/cm-1): 1650 (CO); 1H 
NMR (CDCl3): δ 3.74–3.83 (4H, m, 2’ and 6’-NCH2), 4.04–4.13 (4H, m, 3’ and 5’-OCH2), 4.14 (3H, s,10-Me), 
7.48 (1H, t, J6,7 = J7,8 = 7.8 Hz, 7-H), 7.68 (1H, d, J8,9 = 8.7 Hz, 9-H), 7.85 (1H, dt, J7,8 = 7.8 Hz, J8, 9 = 8.7 Hz, J6,8 = 
1.5 Hz, 8-H), 7.91 (1H, d, J6,7 = 7.8 Hz, 6-H), 8.99 (1 H, s, 5-H); Anal. calcd for C16H16N4O2· 0.4H2O: C, 63.31; H, 
5.58; N, 18.46. Found: C, 63.61; H, 5.84; N, 18.41.  
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4.1.46  10-Methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]quinolin-4-(10H)-one (7h). 
Yield, (1.08 g, 70%); mp 235–237 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 
(4.56), 272 (4.56), 277sh (4.53), 322 (3.99), 382sh (4.06), 407 (4.24), 430 (4.17); IR (νmax/cm-1): 1650 (CO); 1H 
NMR (CDCl3): δ 2.35 (3H, br s, 4’-Me), 2.42–2.58 (4H, m, 3’ and 5’-CH2), 4.06–4.11 (4H, m, 2’ and 6’-CH2), 
4.13 (3H, s,10-Me), 7.46 (1H, t, J6,7 = J7,8 = 7.8 Hz, 7-H), 7.68 (1H, d, J8,9 = 9.0 Hz, 9-H), 7.83 (1H, dt, J7,8 = 7.8 
Hz, J8,9 = 9.0 Hz, J6,8 = 1.5 Hz, 8-H), 7.91 (1H, d, J6,7 = 7.8 Hz, 6-H), 8.96 (1H, s, 5-H); Anal. calcd for C17H19N5O· 
0.4H2O: C, 64.50; H, 6.30; N, 22.12. Found: C, 64.28; H, 6.22; N, 21.92.  
 
4.1.47.  7-Methoxy-10-methyl-2-morpholinopyrimido[4,5-b]quinolin-4-(10H)-one (7i). 
Yield, (1.57 g, 96%); mp 296–299 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 
(4.47), 276 (4.49), 328 (4.03), 400sh (3.92), 427 (4.16), 453 (4.18); IR (νmax/cm-1): 1655 (CO); 1H NMR (CDCl3): 
δ 3.72–3.82 (4H, m, 2’ and 6’-NCH2), 3.93 (3H, s, 7-OMe), 4.00–4.12 (4H, m, 3’ and 5’-OCH2), 4.13 (3H, s, 
10-Me), 7.22 (1H, d, J6,8 = 2.7 Hz, 6-H), 7.47 (1H, dd, J8,9 = 9.3 Hz, J6,8 = 2.7 Hz, 8-H), 7.68 (1H, d, J8,9 = 9.3 Hz, 
9-H), 8.91 (1H, s, 5-H); Anal. calcd for C17H18N4O3· H2O: C, 59.29; H, 5.85; N, 16.27. Found: C, 59.30; H, 5.76; 
N, 15.89.  
 
4.1.48.  7,10-Dimethyl-2-piperidinopyrimido[4,5-b]quinolin-4-(10H)-one (7j). 
Yield, (1.48 g, 96%); mp 292–293 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 222 (4.72), 275 
(4.71), 283sh (4.64), 322 (4.13), 391sh (4.18), 415 (4.38), 440 (4.33); IR (νmax/cm-1): 1640 (CO); 1H NMR 
(CDCl3): δ 1.67 (6H, br s, 3’, 4’ and 5’-CH2), 2.49 (3H, s, 7-Me), 3.97–4.06 (4H, ｍ, 2’ and 6’-CH2), 4.09 (3H, s, 
10-Me), 7.53 (1H, d, J8,9 = 9.3 Hz, 9-H), 7.58–7.65 (2H, m, 6 and 8-H), 8.86 (1H, s, 5-H); Anal. calcd for 
C18H20N4O· 1.1H2O: C, 65.87; H, 6.82; N, 17.07. Found: C, 66.16; H, 7.22; N, 17.16.  
 
4.1.49.  10-Ethyl-7-methyl-2-morpholinopyrimido[4,5-b]quinolin-4-(10H)-one (7k). 
Yield, (1.27 g, 78%); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (4.63), 274 
(4.62), 283sh (4.55), 326 (4.12), 387sh (4.09), 413 (4.32), 437 (4.29);  IR (νmax/cm-1): 1650 (CO); 1H NMR 
(CDCl3): δ 1.48 (3H, t, J = 7.2 Hz, 10-CH2-CH3), 2.51 (3H, s, 7-Me), 3.70–3.85 (4H, m, 2’ and 6’-NCH2), 
3.99–4.16 (4 H, m, 3’ and 5’-OCH2), 4.76 (2H, q, J = 7.2 Hz, 10-CH2-CH3), 7.48 (1H, d, J8,9 = 9.3 Hz, 9-H), 
7.64–7.68 (2H, m, 6 and 8-H), 8.93 (1H, s, 5-H); Anal. calcd for C18H20N4O2: C, 66.65; H, 6.21; N, 17.27. Found: 
C, 66.44; H, 6.37; N, 17.40.  
 
4.1.50.  7-Chloro-10-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]quinolin-4-(10H)-one (7l) 
Yield, (1.46 g, 85%); mp >300 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 (4.65), 
275 (4.65), 284sh (4.59), 319 (4.02), 390sh (4.09), 416 (4.27), 442 (4.21); IR (νmax/cm-1): 1660 (CO); 1H NMR 
(CDCl3): δ 2.34 (3H, s, 4’-Me), 2.45–2.53 (4H, m, 3’ and 5’-CH2), 4.05–4.15 (4H, m, 2’ and 6’-CH2), 4.10 (3H, s, 
10-Me), 7.60 (1H, d, J8,9 = 9.0 Hz, 9-H), 7.75 (1H, dd, J8,9 = 9.0 Hz, J6,8 = 2.1 Hz, 8-H), 7.81 (1H, d, J6,8 = 2.1 Hz, 
6-H), 8.82 (1H, s, 5-H); Anal. calcd for C17H18ClN5O· 0.1H2O: C, 59.08; H, 5.31; N, 20.26. Found: C, 58.72; H, 
5.43; N, 20.69.  
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4.1.51.  7-Chloro-10-methyl-2-piperidinopyrimido[4,5-b]quinolin-4-(10H)-one (7m). 
Yield, (1.46 g, 89%); mp >300 °C (from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 (4.77), 276 
(4.78), 286sh (4.71), 317 (4.11), 393sh (4.24), 420 (4.41), 445 (4.35); IR (νmax/cm-1): 1645 (CO); 1H NMR 
(CDCl3): δ 1.70 (6H, br s, 3’, 4’ and 5’-CH2), 3.96–4.06 (4H, ｍ, 2’ and 6’-NCH2), 4.08 (3H, s, 10-Me), 7.57 (1H, 
d, J8,9 = 9.0 Hz, 9-H), 7.72 (1H, d, J8,9 = 9.0 Hz, 8-H), 7.79 (1H, s, 6-H), 8.79 (1H, s, 5-H); Anal. calcd for 
C17H17ClN4O· 1.1H2O: C, 58.57; H, 5.55; N, 16.07. Found: C, 58.23; H, 5.46; N, 15.82.  
  
4.1.52.  7,8,10-Trimethyl-2-morpholinopyrimido[4,5-b]quinolin-4-(10H)-one (7n). 
Yield, (1.28 g, 79%); mp 287–289 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 225 
(4.75), 276 (4.70), 336 (4.18), 387sh (4.15), 410 (4.38), 434 (4.67); IR (νmax/cm-1): 1650 (CO); 1H NMR (CDCl3): 
δ 2.41 (3H, s, 7-Me), 2.52 (3H, s, 8-Me), 3.73–3.81 (4H, m, 2’ and 6’-NCH2), 4.02–4.09 (4H, m, 3’ and 5’-OCH2), 
4.11 (3H, s, 10-Me), 7.44 (1H, s, 9-H), 7.60 (1H, s, 6 H), 8.91 (1H, s, 5-H); Anal. calcd for C18H20N4O2· 0.4H2O: 
C, 65.20; H, 6.32; N, 16.90. Found: C, 65.05; H, 6.38; N, 17.10. 
  
4.1.53.  7-Methoxy-10-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]quinolin-4-(10H)-one (7o) 
Yield, (1.54 g, 85%); mp 237–239 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 226 
(4.60), 280 (4.68), 327 (4.18), 400sh (4.05), 427 (4.32), 453 (4.34); IR (νmax/cm-1): 1640 (CO); 1H NMR (CDCl3): 
δ 2.34 (3 H, br s, 4’-Me), 2.45–2.53 (4H, m, 3’ and 5’-CH2), 3.92 (3H, s, 7-OMe), 4.04–4.10 (4H, m, 2’ and 
6’-CH2), 4.12 (3H, s, 10-Me), 7.20 (1H, d, J6,8 = 2.7 Hz, 6-H), 7.45 (1H, dd, J8,9 = 9.6 Hz, J6,8 = 2.7 Hz, 8-H), 7.61 
(1H, d, J8,9 = 9.6 Hz, 9-H), 8.89 (1H, s, 5-H); Anal. calcd for C18H21N5O2· 0.4H2O: C, 62.38; H, 6.34; N, 20.21. 
Found: C, 62.65; H, 6.23; N, 19.80.  
 
4.1.54.  10-Ethyl-2-(2-hydroxyethylamino)pyrimido[4,5-b]quinolin-4-(10H)-one (7p). 
Yield, (1.14 g, 80%); mp 267–270 °C (decomp., from DMF); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 221 
(4.42), 268 (4.44), 274sh (4.41), 321 (3.90), 404sh (4.01), 425sh (3.93); IR (νmax/cm-1): 3250 (OH), 3190 (NH), 
1640 (CO); 1H NMR [(CD3)2SO] at 90 °C: δ 1.40 (3H, t, J = 6.9 Hz, 10-CH2-CH3), 3.39–3.50 (2H, m, 
2-NH-CH2-CH2-OH), 3.56–3.62 (2H, m, 2-NH-CH2-CH2-OH), 3.96 (1H, br s, 2-NH-CH2-CH2-OH, exchangeable 
with D2O), 4.80 (2H, q, J = 6.9 Hz, 10-CH2-CH3), 7.19 (1H, br s, 2-NH, exchangeable with D2O), 7.44–7.58 (1H, 
m, 9-H), 7.84–7.98 (1H, m, 7 and 8-H), 8.15 (1H, br d, J6,7 = 8.1 Hz, 6-H), 8.80 (1H, s, 5-H); Anal. calcd for 
C15H16N4O2: C, 63.37; H, 5.67; N, 19.71. Found: C, 63.19; H, 5.73; N, 19.48.  
 
4.1.55.  10-Methyl-2-n-octylaminopyrimido[4,5-b]quinolin-4-(10H)-one (7q). 
Yield, (1.46 g, 86%); mp 183–185 °C (decomp, from EtOH); UV (EtOH): λmax/nm (log ε/dm3 mol–1 cm–1): 220 
(4.60), 269 (4.63), 274sh (4.60), 320 (4.07), 404 (4.19), 422sh (4.15); IR (νmax/cm-1): 3180 (NH), 1655 (CO); 1H 
NMR [(CD3)2SO] at 90 °C: δ 0.86 (3H, t, J = 7.2 Hz, 2-N(CH2)7-CH3), 1.24–1.42 (10H, m, 
2-N(CH2)2-(CH2)5-CH3 ), 1.65 (2H, m, 2-NCH2-CH2 -(CH2)5-CH3), 3.40–3.61 (2H, m, 2-NCH2-(CH2)6-CH3), 4.21 
(3H, s, 10-Me), 7.52–7.74 (1H, m, 7-H), 7.90–8.12 (2H, m, 8 and 9-H), 8.14–8.30 (1H, m, 6-H), 8.85 (1H, br s, 
2-NH, exchangeable with D2O), 9.12 (1H, s, 5-H); Anal. calcd for C20H26N4O: C, 70.98; H, 7.74; N, 16.55. Found: 
C, 70.66; H, 7.59; N, 16.26.  
 27 
 
4.2. Growth inhibitory activities of 2-substituted 10-alkyl-2-deoxo-5-deazaflavins (2–4, 6, 7) and 
5-deazaflavin (5) against human tumor cell lines. 
The procedure was carried out using the modified MTT assay 28 to determine the inhibitory effects of test 
compounds on cell growth in vitro as mentioned in detail in our previous paper.1 Two human tumor cell lines of 
human T-cell acute lymphoblastoid leukemia (CCRF-HSB-2) and human oral epidermoid carcinoma (KB) were 
used in this study. 
 
4.3. Molecular docking study 
 
The advanced docking program AutoDock 3.0.524 was used to evaluate the binding free energy of the inhibitors 
within the macromolecules. The individual components of the program include AutoTors, AutoGrid, and 
AutoDock. AutoTors defines which bonds in the ligand are rotatable, affecting the degrees of freedom (DOF) of 
the ligand and hence the complexity of computations. AutoGrid pre-calculates a three-dimensional grid of 
interaction energies based on the macromolecular target using the AMBER force field. AutoDock performs the task 
of the docking. First, the ligand moves randomly in any one of six degrees of freedom, namely 3 translation 
degrees and 3 rotation degrees, and the energy of the new ligand ‘‘state’’ is calculated. If the energy of the new 
state is lower than that of the old state, the new one is automatically accepted as the next step in docking. 
 
4.3.1. Preparation of ligands and target protein tyrosine kinase  
The compounds involved in this study as ligands include 10-alkyl-2-deoxo-2-methylthio-5-deazaflavins (2a–j), 
2-amino- and 2-(N-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins (3, 4, 6, and 7), and the computationally 
designed compounds connected with amino acids (8a,b) were studied for their binding activities into PTK. Since 
ligands are not peptides, Gasteiger-Hückel charge was assigned and then non-polar hydrogens were merged. The 
rigid roots of each ligands were defined automatically instead of picking manually. The amide bonds were made 
non-rotatable. The three dimensional structures of the aforementioned compounds were constructed using Chem3D 
ultra 8.0 software [Chemical Structure Drawing Standard; Cambridge Soft corporation, USA (2003)], then they 
were energetically minimized by using MOPAC with 100 iterations and minimum RMS gradient of 0.10. The 
crystal structures of c-Kit receptor protein-tyrosine kinase in complex with STI-571 (Imatinib or Gleevec) were 
extracted from the RCSB Protein Data Bank http://www.rcsb.org/pdb/Welcome.do accessed on August, 20, 2005. 
All bound waters, ligand were removed from the protein. For the target, the amino acids of the ligand binding site 
were defined using data in pdbsum http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/ accessed on January 8, 
2006. The polar hydrogen model was chosen for the crystal structure. The proteins were assigned with 
Kollman-united charge. The polar hydrogens and charges were added.  
 
4.3.2. Grid generation and run of molecular docking  
The grid maps representing the native ligand in the actual docking target site were calculated with AutoGrid. The 
grids (one for each atom type in the ligand, plus one for electrostatic interactions) were chosen to be sufficiently 
large to include not only the active site but also significant portions of the surrounding surface. The three 
dimensional grids, 80 Å grid size (x, y, z) with a spacing of 0.375 Å, were created because the location of the 
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native ligand in the crystal structure was known. The cubic grid box was centered in the catalytic active region 
and encompassed the binding site where the ligands were embedded. Then automated docking studies were 
carried out using AutoDock version 3.0.5.24 Of the three different search algorithms offered by AutoDock, the 
GA-LS search algorithm (Genetic algorithm with local search) was chosen to search for the best conformers. The 
parameters were set using the software ADT (Autodock Tool Kit) on PC which is associated with Autodock 
3.0.524.  For all docking parameters, default values were used with 10 independent docking runs for each docking 
case.  
 
4.3.3. Molecular modeling and analysis of the docked results 
There are two kinds of free energies output by Autodock. One is the predicted binding free energy that includes 
the intermolecular energy and torsional free energy, and the other the docking energy that includes the 
intermolecular and intramolecular energies. The former is only reported at the end of a docking operation, while 
the latter is used for selecting better individuals of population during a docking run.24 We used only the binding 
free energy of the first type as the criterion for ranking. Furthermore, the intermolecular hydrogen bonds, whose 
effect has already been counted in the binding energy, were also investigated in order to find useful information 
for drug design. A comparison of the results suggests that the binding free energy is more reliable as a criterion 
for the virtual screening via molecular docking. Cluster analysis was performed on the docked results using a root 
mean square (RMS) tolerance of 0.5. Each of the clusters that exhibited significant negative interaction energies 
was examined by Accelrys, DS modeling 1.7 [Accelrys Inc., San Diego, CA (2006)] to determine their binding 
orientations, molecular modeling, evaluation of the hydrogen bonds and for measuring RMSD, which was 
measured as distance between the centroids of the docked inhibitor and the native ligand. The mode of interaction 
of the native ligand within PTK was used as a standard docked model as well as for RMSD calculation. The 
correct hydrogen bond interaction was considered according to Taylor et al,29 who showed that C–H…O in 
crystals contacts occur within certain distance (3.0–4.0 Å) and angle (C–H…O, 90–180°) ranges. However, the 
more linear hydrogen bond is likely to be more stronger.30 Moreover, there is general agreement that for carbonyl 
acceptors, the H…O=C angle is distributed around 120o. Therefore, in our modeling results we consider the 
hydrogen bond angle ≥ 120° to be of a reasonable strength.  
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